Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2005

View Archived Issues

Antipsychotic 5-HT1A modulators demonstrate anxiolytic properties in preclinical model

Phenoxodiol increases sensitivity of ovarian carcinoma cell lines to docetaxel

Novel dual angiotensin/endothelin receptor antagonist tested in hypertension model

Spectrum acquires rights to RenaZorb

Medicure acquires novel cholesterol-lowering technology platform

1D09C3 enters phase I in B-cell lymphoma patients

Anadis and Starpharma team up on respiratory protection and biodefense work

Six-month review for rhASB in treatment of MSP VI

Prochymal receives fast track designation for acute GVHD

Cortex cleared for phase II Alzheimer's imaging study of CX-717

Flamel and Bristol-Myers Squibb resolve former Basulin license matters

Medicis amends strategic alliance with aaiPharma

PXD-101 enters phase II program for multiple myeloma

SkyePharma and First Horizon extend novel fenofibrate formulation agreement

Toxicity study for FM-VP4

Alizyme opens IND for ATL-962 study in U.S.

New mechanism of mTOR inhibition reported for farnesylthiosalicylic acid

GDNF shows promise as a novel target for treating alcohol abuse

Protease-activated receptors implicated in lower urinary tract inflammation

Cognition unaffected by darifenacin in elderly subjects

New antiinfective agents from Dr. Reddy's

Roche reports new adenosine A2A receptor ligands and use for Parkinson's, depression

Cathepsin K inhibitors emerge from Roche research

Vascular Biogenics discloses series of ether phospholipids in patent

Water-dispersible tablet formulations of lamotrigine patented by Ranbaxy

New compositions of acitretin with enhanced bioavailability

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...